Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$4.6M |
 |
AmarinAMRN |
$1.7M |
 |
Gilead SciencesGILD |
-$233M |
 |
Anavex Life SciencesAVXL |
-$14M |
 |
Inovio PharmaceuticalsINO |
-$2.2M |
Insider Transactions
| Name | Transaction Date | Sold / Bought | Shares | Price | Value |
|---|---|---|---|---|---|
| O'Neill Gilmore Neil | Dec 3, 2024 | Sell | 1,618 | $2.0774 | $3,400 |
| Mei Baisong | Dec 3, 2024 | Sell | 541 | $2.0772 | $1,100 |
| O'Neill Gilmore Neil | Sep 4, 2024 | Sell | 1,555 | $3.4247 | $5,300 |
| Mei Baisong | Sep 4, 2024 | Sell | 518 | $3.4247 | $1,800 |
| Burkly Linda | Jul 25, 2024 | Sell | 11,886 | $5.4156 | $64,000 |
| Mei Baisong | Jul 19, 2024 | Sell | 6,619 | $5.2056 | $34,000 |
| O'Neill Gilmore Neil | Jun 4, 2024 | Sell | 12,191 | $5.4956 | $67,000 |
| Mei Baisong | Jun 4, 2024 | Sell | 511 | $5.4956 | $2,800 |
| Lucera Erick | May 20, 2024 | Sell | 22,337 | $5.6142 | $130,000 |
| Hopfield Jessica | May 13, 2024 | Buy | 45,000 | $5.6415 | $250,000 |
| O'Neill Gilmore Neil | Mar 5, 2024 | Sell | 77,824 | $9.4172 | $730,000 |
| Mei Baisong | Mar 4, 2024 | Sell | 20,327 | $9.4173 | $190,000 |
| Eaton Bruce | Dec 5, 2023 | Sell | 103 | $10.8972 | $1,100 |
| Eaton Bruce | Nov 14, 2023 | Sell | 695 | $8.2096 | $5,700 |
| Eaton Bruce | Nov 7, 2023 | Sell | 139 | $8.4 | $1,200 |
| Eaton Bruce | Sep 6, 2023 | Sell | 103 | $8.82 | $910 |
| Eaton Bruce | Aug 11, 2023 | Sell | 702 | $8.5935 | $6,000 |
| Eaton Bruce | Aug 8, 2023 | Sell | 141 | $8.39 | $1,200 |
| Mei Baisong | Jul 19, 2023 | Sell | 4,317 | $8.8 | $38,000 |
| O'Neill Gilmore Neil | Jun 5, 2023 | Sell | 6,486 | $9.5032 | $62,000 |
| Eaton Bruce | Jun 5, 2023 | Sell | 105 | $9.503 | $1,000 |
| ROBERTSON MICHELLE | May 11, 2023 | Sell | 949 | $9.872 | $9,400 |
| Eaton Bruce | May 11, 2023 | Sell | 668 | $9.872 | $6,600 |
| Eaton Bruce | May 9, 2023 | Sell | 135 | $9.51 | $1,300 |
| ROBERTSON MICHELLE | Mar 3, 2023 | Sell | 184 | $8.89 | $1,600 |
| Eaton Bruce | Mar 3, 2023 | Sell | 101 | $8.89 | $900 |
| Shearman Mark S | Feb 13, 2023 | Sell | 2,790 | $9.6653 | $27,000 |
| ROBERTSON MICHELLE | Feb 13, 2023 | Sell | 4,287 | $9.6653 | $41,000 |
| Eaton Bruce | Feb 13, 2023 | Sell | 3,307 | $9.6653 | $32,000 |
| Eaton Bruce | Feb 7, 2023 | Sell | 346 | $11.1 | $3,800 |
| ROBERTSON MICHELLE | Jan 10, 2023 | Sell | 1,752 | $8.1601 | $14,000 |
What's the latest insider transaction for Editas Medicine?
The most recent insider transaction for Editas Medicine was conducted by O'Neill Gilmore Neil, who sold 1,618 shares on December 3, 2024 at a price of $2.08 per share.
Which insider bought the most EDIT stock over the last two years?
Hopfield Jessica has bought the most EDIT stock in the last 2 years, with a total value of $250,000.
Which insider has sold the most EDIT stock over the last two years?
O'Neill Gilmore Neil has sold the most EDIT stock in the last 2 years, with a total value of $870,000.
What is the total value of insider transactions for Editas Medicine (EDIT) in the last 2 years?
The total value of insider transactions for Editas Medicine in the last 2 years is negative, amounting to -$1.2M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
How do insider transactions over the last 2 years reflect on Editas Medicine's market confidence?
Over the last 2 years, insider transactions for Editas Medicine have largely consisted of selling shares, which could suggest various personal or financial motivations among insiders. The higher number of sales might require investors to investigate further, considering insiders might have insights or reasons not immediately apparent to the public.
Why is monitoring insider trading activity important for investors?
Monitoring insider trading activity is important because it provides insights into the confidence levels of a company's insiders, such as executives and directors, regarding the company's future prospects. Insider buying can signal optimism, suggesting the stock may be undervalued, while insider selling might raise questions about the stock's upcoming performance. However, it's essential to consider that sales can also occur for personal financial reasons. Insider trading activity is a valuable indicator that, when combined with other data, can help inform investment decisions.
